UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

GE HEALTHCARE LTD.,
Petitioner

v.

THE JOHNS HOPKINS UNIVERSITY,
Patent Owner

Case IPR2026-00069
U.S. Patent No. 11,938,201

PATENT OWNER'S UPDATED EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Patent Owner The Johns Hopkins University ("Patent Owner") submits this Updated Exhibit List to accompany submission of Exhibit 2060, the transcript of a teleconference held between the Board and parties on July 27, 2026.

PATENT OWNER'S UPDATED EXHIBIT LIST

Exhibit No.	Description
2001	Declaration of Dr. Henry VanBrocklin in Support of Patent Owner Preliminary Response
2002	*Curriculum vitae* of Dr. Henry VanBrocklin
2003	Jansen *et al.*, "Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold," *MedChemComm* (August 2014) ("Jansen 2014")
2004	Sikkandhar *et al.*, "Theranostic Probes for Targeting Tumor Microenvironment: An Overview," *International Journal of Molecular Sciences* (May 2017) ("Sikkandhar")
2005-2010	*Intentionally Left Blank*
2011	Slania *et al.*, "Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2 cyanopyrrolidine-Based Small Molecules," *Journal of Medicinal Chemistry* (April 2021) ("Slania")
2012-2017	*Intentionally Left Blank*
2018	Bvumbi, M., "Activity of Riminophenazines against Mycobacterium tuberculosis: A Review of Studies that Might be Contenders for Use as Antituberculosis Agents," ChemMedChem 15(23):2207-2219 (December 2020) ("Bvumbi")
2019	Xu et al., "Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors," Bioorganic & Medicinal Chemistry Letters, 15:2533-2536 (May 2005) ("Xu 2005")

Exhibit No.	Description
2020	Calcaterra et al., "Classics in Chemical Neuroscience: Diazepam (Valium)," ACS Chemical Neuroscience, 5:253-260 (February 2014) ("Calcaterra")
2021	Lever, A.B.P., "Lewis Structures and the Octet Rule," Journal of Chemical Education, 49(12):819-821 (December 1972) ("Lever")
2022	Errata to Declaration of Dr. Brian Dr. Zeglis (EX1003) (submitted as Exhibit 2018 in PGR2025-00059)
2023	Dr. Zeglis *et al*., "Radiopharmaceuticals for Imaging in Oncology with Special Emphasis on Positron Emitting Agents," Chapter 3 of *Nuclear Oncology: Pathophysiology and Clinical Applications*, H.W. Strauss *et al*., eds. (2013) ("Dr. Zeglis 2013 II")
2024	Poplawski *et al*., "Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase," *J Med Chem.* 56(9): 3467–3477 (May 9, 2013) ("Poplawski") (submitted as Exhibit 2020 in PGR2025-00059)
2025	Pages 7 and 8 of U.S. Patent Application Publication No. 2010/0098633 A1 (EX1004) (annotated by Dr. Brian Dr. Zeglis) (submitted as Exhibit 2021 in PGR2025-00059)
2026	Pages 12–14 of U.S. Patent Application Publication No. 2010/0098633 A1 (EX1004) (annotated by Dr. Brian Dr. Zeglis) (submitted as Exhibit 2022 in PGR2025-00059)
2027	Transcript of the Deposition of Dr. Brian Dr. Zeglis, March 11, 2026
2028	Sugiura *et al*., "Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs," *Molecules* 19: 2135–2165 (2014) ("Sugiura")
2029	Testa *et al*., "The influence of lipophilicity on the pharmacokinetic behavior of drugs: Concepts and examples," *Perspectives in Drug Discovery and Design*, 19: 179–211 (2000) ("Testa")

Exhibit No.	Description
2030	Siwowska *et al*., "Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties," *Molecular Pharmaceutics*, 14(2): 523–532 (2017) ("Siwowska")
2031	Fischer *et al*., "Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies," *Clinical Cancer Research*, 18(22): 6208–6218 (November 15, 2012) ("Fischer")
2032	Scott *et al*., "A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer," *Clinical Cancer Research*, 9: 1639–1647 (May 2003) ("Scott")
2033	Welt *et al*., "Antibody Targeting in Metastatic Colon Cancer: A Phase I Study of Monoclonal Antibody F19 Against a Cell-Surface Protein of Reactive Tumor Stromal Fibroblasts," *Journal of Clinical Oncology*, 12(6): 1193–1203 (June 1994) ("Welt")
2034	Aertgeerts *et al*., "Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein α," *The Journal of Biological Chemistry*, 280(20): 19441–19444 (May 20, 2005) ("Aertgeerts")
2035	Laverman *et al*., "Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti–Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis," *The Journal of Nuclear Medicine*, 56(5): 778–783 (May 2015) ("Laverman")
2036	Rüger *et al*., "*In vivo* near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes," *Journal of Controlled Release*, 184: 1–10 (2014) ("Rüger")
2037	LeBeau *et al.*, "Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin," *Molecular Cancer Therapy*, 8(5): 1378–1386 (May 2009) ("LeBeau")

Exhibit No.	Description
2038	Huang *et al*., "Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug," *Journal of Drug Targeting*, 19(7): 487–496 (2011) ("Huang")
2039	Keane *et al*., "Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α," *FEBS Journal*, 278: 1316–1332 (2011) ("Keane")
2040	Reiner *et al*., "Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging," *Journal of Visualized Experiments*, 96 (February 2015) ("Zeglis 2015")
2041	Adumeau *et* al., "Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 1: Cysteine Residues and Glycans," *Molecular Imaging Biology*, 18: 1–17 (2016) ("Zeglis 2016")
2042	Zeglis *et al*., "Chemoenzymatic Strategy for the Synthesis of Site-Specifically Labeled Immunoconjugates for Multimodal PET and Optical Imaging," *Bioconjugate Chemistry*, 25(12): 2123–2128 (November 24, 2014) ("Zeglis 2014")
2043	Penner *et al*., "Radiolabeled Absorption, Distribution, Metabolism, and Excretion Studies in Drug Development: Why, When, and How?" *Chemical Research in Toxicology*, 25: 513–531 (2012) ("Penner")
2044	Jensen, "The Origins of the Ortho-, Meta-, and Para- Prefixes in Chemical Nomenclature." *Journal of Chemical Education*, 83(3): 1-2 (2006).
2045	International Patent Appl. No. PCT/US2022/023374, published as WO 2022/212958 ("WO '958")
2046	Xu *et al*., "Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy," *The Journal of Nuclear Medicine*, 63(6):952-958 (June 2022) ("Xu")

Exhibit No.	Description
2047	Declaration of Dr. Henry VanBrocklin in Support of Patent Owner Response
2048-2059	*Intentionally Left Blank*
2060	Teleconference Transcript, July 27, 2026

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Christopher M. Gallo/

Christopher M. Gallo, Ph.D.
Registration No. 70,291
Back-up Counsel for Patent Owner

Date: August 10, 2026

1101 K Street, NW
10th Floor
Washington, DC 20005
(202) 371-2600

CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))

I certify that the above-captioned **PATENT OWNER'S UPDATED EXHIBIT LIST** and associated Exhibit 2060 were served in their entireties on August 10, 2026, upon the following parties via electronic mail:

Jeffrey P. Kushan (Lead Counsel)
Lauren Katzeff (Back-up Counsel)
Amit Bhatla (Back-up Counsel)
SIDLEY AUSTIN LLP
jkushan@sidley.com
lkatzeff@sidley.com
abhatla@sidley.com

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Christopher M. Gallo/

Christopher M. Gallo, Ph.D.
Registration No. 70,291
Back-up Counsel for Patent Owner

Date: August 10, 2026

1101 K Street, NW
10th Floor
Washington, DC 20005
(202) 371-2600